Zithranol

Manufacturer
Elorac Inc. | Elorac, Inc.
Effective date
2014-10-17
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
full-release
Hydrated at
2026-05-31 20:19:37

Label at a glance#

ProductZithranol
Active ingredientAnthralin
Label structure4 sections

Label contents#

Full prescribing information#

Zithranol Shampoo anthralin 1% | microcrystalline-encapsulated system Package Insert:

SPL PATIENT PACKAGE INSERT SECTION

SPL UNCLASSIFIED SECTION

Rx Only

FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE

DESCRIPTION

DESCRIPTION SECTION

Zithranol Shampoo contains 1% anthralin in a shampoo base containing glyceryl monolaurate, glyceryl monomyristate, citric acid, sodium hydroxide, FD&C Blue No. 1, Macare® G-2C, and purified water. The chemical name of anthralin is 1,8-dihydroxy-9-anthrone and its structural formula is:

zithranol structure - 17Oct2014 adjusted.jpg
zithranol structure - 17Oct2014 adjusted.jpg

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Zithranol Shampoo contains anthralin, a synthetic compound whose precise mechanism of antipsoriatic action is not yet fully understood. However, numerous studies have demonstrated antiproliferative and antiinflammatory effects of anthralin on psoriatic and normal skin. The antiproliferative effects of anthralin appear to result from both an inhibition of DNA synthesis as well as from its strong reducing properties. Recently, anthralin’s effectiveness as an antipsoriatic agent has also been in part attributed to its ability to induce lipid peroxidation and reduce levels of endothelial adhesion molecules, which are markedly elevated in psoriatic patients. Unlike retinoids and PUVA, anthralin does not inhibit liver microsomal enzyme activity; consequently, the likelihood of adverse drug interactions is greatly reduced when other agents are administered concomitantly with anthralin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Zithranol Shampoo for the treatment of scalp psoriasis in subjects 12 years of age and older (see PRECAUTIONS). Patients should be instructed to use Zithranol Shampoo for the minimum time period necessary to achieve the desired results.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Use of Zithranol Shampoo is contraindicated in patients who are hypersensitive to anthralin or to any ingredient in this preparation.

WARNINGS

WARNINGS SECTION

Avoid contact with the eyes or mucous membranes. Discontinue use if a sensitivity reaction occurs or if excessive irritation develops.

PRECAUTIONS

GENERAL PRECAUTIONS SECTION

General: For external use only. Contact with fabrics, plastics and other materials may cause staining and should be avoided. Always wash hands thoroughly after use. Keep container tightly capped when not in use. Avoid excessive heat. Keep out of the reach of children.

Carcinogenesis, mutagenesis, impairment of fertility: Although long-term studies in animals have not been performed to evaluate the carcinogenic potential of the drug, there have been no reports to suggest carcinogenic effects in humans after many years of clinical use.

Pregnancy:
Teratogenic Effects: Pregnancy Category C
Animal reproduction studies have not been conducted with Zithranol Shampoo. It is also not known whether Zithranol Shampoo can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Zithranol Shampoo should be given to a pregnant woman only if clearly needed.

Nursing mothers: Because many drugs are excreted in human milk, caution should be exercised when Zithranol Shampoo is administered to a nursing woman.

Pediatric use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Very few instances of contact allergic reactions to anthralin have been reported. Transient primary irritation and staining of hair or skin may occur. The temporary discoloration of hair and skin may be minimized by careful application. Staining of fabrics may be permanent so contact should be avoided.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Zithranol Shampoo should be applied onto wet scalp 3 to 4 times per week (or as directed by the physician). Lather and leave on scalp for 3 to 5 minutes and then rinse thoroughly. Avoid contact with eyes. Although no additional shampoo is necessary to cleanse the hair, a non-medicated shampoo or conditioner can be applied following the use of Zithranol Shampoo, if desired. If no improvement is seen after 4 weeks of treatment, consult the physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Zithranol Shampoo (anthralin 1%) microcrystalline-encapsulated system is supplied in tubes.

85g NDC 42783-111-85
7.5g NDC 42783-111-07
(physician sample size)

Store at controlled room temperature 68°F to 77°F (20°C to 25°C).

Manufactured for:
Elorac, Inc.
Vernon Hills, IL 60061

U.S. Patent Pending

Caution: Federal law prohibits dispensing without prescription.

© 2011 Elorac, Inc.


Rev. 01 (10/2011)

TUBE AND CARTON PHOTO:

Zithranol Shampoo Tube and Carton Photo - adjusted 17Oct2014 clm.jpgZithranol Shampoo Tube and Carton Photo - adjusted 17Oct2014 clm.jpg

Zithranol Shampoo anthralin 1% | microcrystalline encapsulated system    85g Carton Label:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-111-85

Zithranol Shampoo
anthralin 1% | microcrystalline-encapsulated system
85g

FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE

Rx only

zithranol-shampoo-carton.jpg
zithranol-shampoo-carton.jpg

Zithranol Shampoo  anthralin 1% | microcrystalline encapsulated system   85g Container Label:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-111-85

Zithranol Shampoo
anthralin 1% | microcrystalline-encapsulated system
85g

FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE

Rx only

zithranol-shampoo-85-gram-tube.jpg
zithranol-shampoo-85-gram-tube.jpg

Zithranol Shampoo anthralin 1% | microcrystalline-encapsulated system 7.5g Physician Sample Container Label:

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 42783-111-07

Zithranol Shampoo
anthralin 1% | microcrystalline-encapsulated system
7.5g

FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE

Rx only

image description
image description

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1245899anthralin 1 % Medicated ShampooPSN7
1245904ZITHRANOL 1 % Medicated ShampooPSN7
1245904anthralin 10 MG/ML Medicated Shampoo [Zithranol]SBD7
1245899anthralin 10 MG/ML Medicated ShampooSCD7
1245899anthralin 1 % Medicated ShampooSY7
1245904Zithranol 1 % Medicated ShampooSY7
1245904Zithranol 10 MG/ML Medicated ShampooSY7

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
42783-111-072020-01-31C16284748780-19d75b9cf-e19e-f424-e053-dadaa90a57ce253fdee7-5060-4b49-ad26-257eb54cccfa
42783-111-852020-01-31C16284748780-19d75b9cf-e19e-f424-e053-dadaa90a57ce253fdee7-5060-4b49-ad26-257eb54cccfa

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
42783-111-07Zithranol1 in 1 CARTONSHAMPOO17
42783-111-07Zithranol24 in 1 CASESHAMPOO247
42783-111-85Zithranol12 in 1 CASESHAMPOO127
42783-111-85Zithranol1 in 1 CARTONSHAMPOO17

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
42783-111ZITHRANOL (ANTHRALIN) SHAMPOO [ELORAC INC.]7Legacy NDC, 4 package rows20141018_253fdee7-5060-4b49-ad26-257eb54cccfa.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
42783-111-85GM - Gram42783-111f895bba1-7c77-49cf-beab-fee8c0d9f12e12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
AnthralinACTIVE INGREDIENTU8CJK0JH5M7
AnthralinACTIVE MOIETYU8CJK0JH5M7
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QP7
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD7
GLYCERETH-2 COCOATEINACTIVE INGREDIENTJWM00VS7HC7
GLYCERYL LAURATEINACTIVE INGREDIENTY98611C0877
GLYCERYL MYRISTATEINACTIVE INGREDIENT6992Y818277
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I7
WATERINACTIVE INGREDIENT059QF0KO0R7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
42783-11142783-111-85, 42783-111-07

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 302 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR1 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / RECTALNAExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSHAMPOO / TOPICAL17 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / PERINEURALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS385 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRACAVITARYADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM / VAGINAL0.19 %w/wExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSHAMPOO, SUSPENSION / TOPICAL0.25 %w/vExact identifier — unii candidate
88 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINHALANT / RESPIRATORY (INHALATION)NAExact identifier — unii candidate
88 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPLIQUID / ORAL114 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGRANULE, FOR SUSPENSION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSPRAY, METERED / NASAL2 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET, DELAYED RELEASE / ORAL0.01 mgExact identifier — unii candidate
37 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPGRANULE, FOR SUSPENSION / ORAL113 mgExact identifier — unii candidate
88 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / INTRAVENOUS396 mgExact identifier — unii candidate
88 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDELIXIR / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSUSPENSION / ORAL269 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSOLUTION/ DROPS / AURICULAR (OTIC)0.04 %w/wExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION, CONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / SOFT TISSUEADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / PERIODONTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPSYSTEM / TOPICAL0.2 mgExact identifier — unii candidate
88 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPTROCHE / ORAL12 mgExact identifier — unii candidate
88 equally ranked IID candidates
GLYCERYL LAURATEGLYCERYL LAURATEY98611C087SYSTEM / TOPICAL4 mgExact identifier — unii candidate
3 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRABURSALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCREAM / TOPICAL0.01 %w/wExact identifier — unii candidate
37 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SOLUTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPINJECTION, SOLUTION / SUBCUTANEOUS26 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRACARDIACADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED / ORAL0.08 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR5.4 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / SUBCUTANEOUSNAExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL / OPHTHALMIC6 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / ORAL9120 mgExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPLIQUID / INTRAVENOUS0.2 %w/vExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ILIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPLOTION / TOPICAL0.85 %w/wExact identifier — unii candidate
88 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDFILM / SUBLINGUAL0.07 mgExact identifier — unii candidate
37 equally ranked IID candidates
CITRIC ACID MONOHYDRATECITRIC ACID MONOHYDRATE2968PHW8QPTABLET, ORALLY DISINTEGRATING / ORAL83 mgExact identifier — unii candidate
88 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ITABLET, FILM COATED / ORAL8 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INFILTRATIONADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IPOWDER, FOR SOLUTION / ORALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDLIQUID / TOPICALNAExact identifier — unii candidate
37 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
29705f8e-766e-4ef9-9ca7-3e9a9dee9daa253fdee7-5060-4b49-ad26-257eb54cccfa2014-10-17Warnings, Adverse reactionsExact identifier
spl id: 29705f8e-766e-4ef9-9ca7-3e9a9dee9daa
spl set id: 253fdee7-5060-4b49-ad26-257eb54cccfa

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.